UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone

Clinical endocrinology (Oxford), 2020-11, Vol.93 (5), p.620-628

2020

Volltextzugriff (PDF)

Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial

Clinical pharmacokinetics, 2024-07, Vol.63 (7), p.1015-1024

2024

Volltextzugriff (PDF)

Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials

Clinical pharmacokinetics, 2021-08, Vol.60 (8), p.1015-1027

2021

Volltextzugriff (PDF)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3

The journal of clinical endocrinology and metabolism, 2023-09, Vol.108 (10), p.2569-2578

2023

Volltextzugriff (PDF)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan

The journal of clinical endocrinology and metabolism, 2021-02, Vol.106 (2), p.567-576

2021

Volltextzugriff (PDF)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial

The journal of clinical endocrinology and metabolism, 2020-04, Vol.105 (4), p.e1358-e1376

2020

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults

Clinical pharmacokinetics, 2021-09, Vol.60 (9), p.1217-1226

2021

Volltextzugriff (PDF)

Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis

The Journal of physiology, 2010-01, Vol.588 (2), p.341-351

2010

Volltextzugriff (PDF)

Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency

The journal of clinical endocrinology and metabolism, 2016-03, Vol.101 (3), p.988-998

2016

Volltextzugriff (PDF)

Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics

European journal of endocrinology, 2011-09, Vol.165 (3), p.401-409

2011

Volltextzugriff (PDF)

A Reversible Albumin-Binding Growth Hormone Derivative is Well Tolerated and Possesses a Potential Once-Weekly Treatment Profile

The journal of clinical endocrinology and metabolism, 2014-10, Vol.99 (10), p.E1819-E1829

2014

Volltextzugriff (PDF)

Pegylated Long-Acting Human Growth Hormone Is Well-Tolerated in Healthy Subjects and Possesses a Potential Once-Weekly Pharmacokinetic and Pharmacodynamic Treatment Profile

The journal of clinical endocrinology and metabolism, 2010-07, Vol.95 (7), p.3411-3417

2010

Volltextzugriff (PDF)

Pegylated Long-Acting Human Growth Hormone Possesses a Promising Once-Weekly Treatment Profile, and Multiple Dosing Is Well Tolerated in Adult Patients with Growth Hormone Deficiency

The journal of clinical endocrinology and metabolism, 2011-03, Vol.96 (3), p.681-688

2011

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials

Clinical pharmacokinetics, 2019-01, Vol.58 (1), p.63-75

2019

Volltextzugriff (PDF)

Obesity, growth hormone and weight loss

Molecular and cellular endocrinology, 2010-03, Vol.316 (2), p.147-153

Rasmussen, Michael Højby

2010

Volltextzugriff (PDF)

Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects

European journal of pharmaceutical sciences, 2021-12, Vol.167, p.106030, Article 106030

2021

Volltextzugriff (PDF)

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial

The journal of clinical endocrinology and metabolism, 2022-12, Vol.107 (12), p.3378-3388

2022

Volltextzugriff (PDF)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3

The journal of clinical endocrinology and metabolism, 2022-04, Vol.107 (5), p.1357-1367

2022

Volltextzugriff (PDF)

Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial

European journal of endocrinology, 2007-03, Vol.156 (3), p.341-351

2007

Volltextzugriff (PDF)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH

The journal of clinical endocrinology and metabolism, 2023-11, Vol.108 (12), p.3090-3099

2023

Volltextzugriff (PDF)

Understanding burden of illness for child growth hormone deficiency

Quality of life research, 2017-07, Vol.26 (7), p.1673-1686

2017

Volltextzugriff (PDF)

Letter to the Editor From Sävendahl et al.: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial"

The journal of clinical endocrinology and metabolism, 2022-02, Vol.107 (2), p.e888-e889

2022

Volltextzugriff (PDF)

Effects of short-term caloric restriction on circulating free IGF-I, acid-labile subunit, IGF-binding proteins (IGFBPs)-1-4, and IGFBPs-1-3 protease activity in obese subjects

European journal of endocrinology, 2006-10, Vol.155 (4), p.575-581

2006

Volltextzugriff (PDF)

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”

The journal of clinical endocrinology and metabolism, 2023-08, Vol.108 (8), p.e647-e648

2023

Volltextzugriff (PDF)

Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency

European journal of endocrinology, 2022-07, Vol.187 (1), p.27-38

2022

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(93)

Sprache

Englisch
(91)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(54)
Science & Technology
(54)
Humans
(49)
Endocrinology & Metabolism
(40)
Adult
(33)
Male
(33)
Female
(26)
Biological And Medical Sciences
(20)
Growth Hormones
(20)
Medical Sciences
(17)
Double-Blind Method
(15)
Human Growth Hormone - Administration & Dosage
(15)
Middle Aged
(15)
Child
(14)
Insulin-Like Growth Factor I - Metabolism
(14)
Insulin-Like Growth Factor I
(12)
Aged
(11)
Dwarfism, Pituitary - Drug Therapy
(11)
Growth Hormone
(11)
Original
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone

Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial

Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults

Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis

Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency

Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics

A Reversible Albumin-Binding Growth Hormone Derivative is Well Tolerated and Possesses a Potential Once-Weekly Treatment Profile

Pegylated Long-Acting Human Growth Hormone Is Well-Tolerated in Healthy Subjects and Possesses a Potential Once-Weekly Pharmacokinetic and Pharmacodynamic Treatment Profile

Pegylated Long-Acting Human Growth Hormone Possesses a Promising Once-Weekly Treatment Profile, and Multiple Dosing Is Well Tolerated in Adult Patients with Growth Hormone Deficiency

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials

Obesity, growth hormone and weight loss

Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3

Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH

Understanding burden of illness for child growth hormone deficiency

Letter to the Editor From Sävendahl et al.: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial"

Effects of short-term caloric restriction on circulating free IGF-I, acid-labile subunit, IGF-binding proteins (IGFBPs)-1-4, and IGFBPs-1-3 protease activity in obese subjects

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”

Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency

Suchergebnisse filtern